

International Journal of Molecular Medicine

ISSN 1107-3756
eISSN 1791-244X

VOLUME 44, SUPPLEMENT 1, 2019



**Proceedings of the Abstracts of
The 24th World Congress on Advances in Oncology,
and
24th International Symposium on Molecular Medicine**

**10-12 October, 2019, Mystras Grand Palace Resort,
Sparta, Greece**

International Journal of Molecular Medicine

ISSN 1107-3756
eISSN 1791-244X

Editor in Chief

DEMETRIOS A. SPANDIDOS, BSc, PhD, FRCPath, DSc, FRSH, FASA
Professor Emeritus, Medical School, University of Crete, Heraklion, Greece
Spandidos Publications, Greece

Deputy Editors

ATHANASIA SPANDIDOS, BSc (Hons), PhD
Faculty Member, Department of Biomedical Sciences, University of Greenwich, Athens, Greece
Spandidos Publications, Greece

NIKIFOROS A. SPANDIDOS, BSc (Hons), MSc, PhD
Spandidos Publications, United Kingdom

Fax: +30 210 725 2922; Tel: +30 210 722 7809
e-mail: contact@spandidos-publications.com
Web-site: www.spandidos-publications.com

Submission of manuscripts

Online: www.spandidos-publications.com

By courier service/overnight mail: Professor D.A. Spandidos,
Editorial Office: 10, Vriaxidos Street, Athens 116 35, Greece

Aims and scope: *International Journal of Molecular Medicine* is a journal providing rapid publication in the field of molecular and clinical research on the mechanisms of diseases related to man, including biology, biochemistry, physiology, immunology, pharmacology, pathology, gene therapy, genetics, virology, hematology, endocrinology, microbiology, oncology, epidemiology, neurosciences, infectious diseases, molecular pathogenesis, human genomics, molecular cardiology, molecular surgery, molecular psychology. Studies *in vitro* or *in vivo* on experimental model systems relevant to the mechanisms of disease are also considered. All manuscripts submitted to the *International Journal of Molecular Medicine* are subject to review.

Publication data: *International Journal of Molecular Medicine* is published monthly.

Annual subscription rates: Print and online subscription rates available at contact@spandidos-publications.com

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the *International Journal of Molecular Medicine*, provided that the base fee of US\$32.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy licence by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 1019-6439/93 US\$32.00 + 0.40.

Editorial board:

The Editorial Board of the *International Journal of Molecular Medicine* consists of experts in their field who are members of The Editorial Academy of the *International Journal of Molecular Medicine*.

Editorial Academy of the International Journal of Molecular Medicine:

To qualify as a member of The Editorial Academy each editor must have 1000 citations of his work as first author or over 2000 in total or over 100 publications in refereed journals and to have contributed significantly to molecular medicine. To apply to become a member of The Editorial Academy you should submit your CV to the Editorial Office.

Bibliographic services: Articles in the *International Journal of Molecular Medicine* are listed in bibliographic services including Current Contents/Life Sciences, Index Medicus, MEDLINE, PubMed Central, Science Citation Index, Biochemistry & Biophysics Citation Index, Science Citation Index Expanded (SciSearch), ISI Web of Science, Chemical Abstracts, BIOSIS and Index Copernicus.

The Editors and Publishers of *International Journal of Molecular Medicine* accept no responsibility for the opinions expressed by the contributors appearing herein.

Copyright: Once the manuscript has been published the legal ownership of all published parts of the paper has passed from the Author(s) to the journal.

International Journal of Molecular Medicine

ISSN 1107-3756
eISSN 1791-244X

Editorial Board

- **ALFRED L.M. BOTHWELL**
Yale University School of Medicine, USA
- **BRENDAN F. BOYCE**
University of Rochester Medical Center, USA
- **GIOVANNI CAMUSSI**
University of Turin, Italy
- **GEORGE CHACONAS**
University of Calgary, Canada
- **JEROLD CHUN**
Sanford Burnham Prebys Medical Discovery Institute, USA
- **LUCIO I.M. COCCO**
University of Bologna, Italy
- **MAX D. COOPER**
Emory University School of Medicine, USA
- **RONALD W. DAVIS**
Stanford Genome Technology Center, USA
- **TED M. DAWSON**
Johns Hopkins University School of Medicine, USA
- **MICHELE DE LUCA**
University of Modena and Reggio Emilia, Italy
- **PIERRE DESREUMAUX**
Lille Hospital, Huriez Hospital, France
- **RONALD C. DESROSIERS**
Harvard Medical School, USA
- **E.T. DETORAKIS**
University of Crete, Greece
- **KARL DRLICA**
New Jersey Medical School, Rutgers, USA
- **DENIS DUBOULE**
University of Geneva, Switzerland
- **IAN D. DUNCAN**
University of Wisconsin-Madison, USA
- **MARK J. DUNNE**
University of Manchester, UK
- **TOMAS J. EKSTRÖM**
Karolinska Institutet, Sweden
- **JACK A. ELIAS**
Brown University, USA
- **MAGDY EL-SALHY**
Stord Helse-Fonna Hospital, Norway
- **JONAS NYGAARD ERIKSEN**
Aarhus University, Denmark
- **DAVID FELDMAN**
Stanford University School of Medicine, USA
- **VICENTE FELIPO**
Prince Felipe Research Center, Spain
- **GARY S. FIRESTEIN**
University of California, USA
- **DAVID C. FISHER**
Dana-Farber Cancer Institute, USA
- **GERHARD FRITZ**
Heinrich Heine University Düsseldorf, Germany
- **AKIYOSHI FUKAMIZU**
University of Tsukuba, Japan
- **ARNOLD GANSER**
Hannover Medical School, Germany
- **WILLIAM A. GODDARD III**
Materials and Process Simulation Center, USA
- **JOHN GROFFEN**
University of Southern California, USA
- **H. HONDA**
Yokohama Rehabilitation Center, Japan
- **RANDALL E. HARRIS**
The Ohio State University, USA
- **BARTON FORD HAYNES**
Duke University School of Medicine, USA
- **NORA C. HEISTERKAMP**
Beckman Research Institute City of Hope, USA
- **JOHAN HOEBEKE**
Institute of Molecular and Cell Biology (IBMC), France
- **TAKAHIKO HORIUCHI**
Kyushu University Beppu Hospital, Japan
- **TOMAS HÖKFELT**
Karolinska Institutet, Sweden
- **MITSUO IKEBE**
University of Massachusetts Medical School, USA
- **WEN GUO JIANG**
Cardiff University School of Medicine, UK
- **LEVON MICHAEL KHACHIGIAN**
University of New South Wales, Australia
- **HIROSHI KIJIMA**
Hirosaki University Graduate School of Medicine, Japan
- **KEE-HONG KIM**
Purdue University, USA
- **NAM DEUK KIM**
Pusan National University, Republic of Korea
- **DENNIS M. KLINMAN**
NIH Center for Cancer Research, USA
- **MALAK KOTB**
University of North Dakota, USA
- **CATHARINA LARSSON**
Karolinska University Hospital Solna, Sweden
- **NORBERT LATRUFFE**
University of Burgundy, France
- **ROBERT A. LEVINE**
Massachusetts General Hospital, USA
- **CHARLES LIEBOW**
University of Connecticut Health Center, USA
- **YOUHUA LIU**
University of Pittsburgh, USA
- **YOKE PENG LOH**
Eunice Kennedy Shriver Nat. Inst. of Child Health & Human Develop., USA
- **JOSEPH LOSCALZO**
Brigham and Women's Hospital, USA
- **TIMOTHY J. MCDONNELL**
University of Texas MD Anderson Cancer Center, USA
- **KENNETH MAIESE**
UMDNJ-New Jersey Medical School, USA
- **WILLY J. MALAISSE**
Brussels Free University, Belgium
- **LUDWIK KAZIMIERZ MALENDOWICZ**
Poznan University of Medical Sciences, Poland
- **DARIO MARCHETTI**
Houston Methodist Research Institute, USA
- **CARLOS MARTÍNEZ-A**
National Center for Biotechnology (CNB-CSIC), Spain
- **JEAN MARTINEZ**
University of Montpellier, France
- **YOSHINORI MARUNAKA**
Kyoto Prefectural University of Medicine, Japan
- **IAN W. MATTAJ**
European Molecular Biology Laboratory (EMBL) Heidelberg, Germany
- **MAKOTO MAYUMI**
Jichi Medical School, Japan
- **LAURENCE J. MILLER**
Mayo Graduate School of Medicine, USA

- **TAKASHI MINEGISHI**
Gunma University Graduate School of Medicine, Japan
- **JAMES I. MORGAN**
St. Jude Children's Research Hospital, USA
- **MASAYOSHI NAMBA**
Okayama University Medical School, Japan
- **MARKUS F. NEURATH**
Friedrich-Alexander University, Germany
- **RACHAEL L. NEVE**
McGovern Institute for Brain Research at MIT, USA
- **FERDINANDO ROSARIO NICOLETTI**
University of Catania, Italy
- **GUNILLA OLIVECRONA**
Umeå University, Sweden
- **PAL PACHER**
National Institute on Alcohol Abuse and Alcoholism, USA
- **VASSILIOS PAPADOPOULOS**
University of Southern California, USA
- **KLAUS PFIZENMAIER**
University Hospital Regensburg, Germany
- **MICHAEL POLLAK**
McGill University, Canada
- **WILLIAM A. PRYOR**
Louisiana State University, USA
- **KATYA RAVID**
Boston University School of Medicine, USA
- **MARTIN C. RECHSTEINER**
University of Utah School of Medicine, USA
- **HORACIO RICO**
University of Alcalá, Spain
- **SIMON C. ROBSON**
Harvard Medical School, USA
- **JACK A. ROTH**
University of Texas MD Anderson Cancer Center, USA
- **IKUO SAIKI**
University of Toyama, Japan
- **GAETANO SANTULLI**
Montefiore University Hospital, USA
- **ANDREW V. SCHALLY**
University of Miami, USA
- **CLAUS SCHEIDEREIT**
Max Delbrück Center for Molecular Medicine (MDC), Germany
- **STUART FRANKLIN SCHLOSSMAN**
Dana Farber Cancer Institute, USA
- **AVITAL SCHURR**
University of Louisville, School of Medicine, USA
- **TERRENCE J. SEJNOWSKI**
The Salk Institute for Biological Sciences, USA
- **TSUKASA SEYA**
Hokkaido University Graduate School of Medicine, Japan
- **JERRY W. SHAY**
University of Texas Southwestern Medical Center, USA
- **CHANGSHUN SHAO**
Soochow University, P.R. China
- **YUN-BO SHI**
Eunice Kennedy Shriver NICHD, US National Institutes of Health, USA
- **KAI SIMONS**
Max Planck Institute of Molecular Cell Biology and Genetics, Germany
- **GEORGE B. STEFANO**
First Faculty of Medicine, Charles University, Czech Republic
- **WALTER J. STORKUS**
University of Pittsburgh School of Medicine, USA
- **ANDREAS STRASSER**
Walter and Elizer Hall Institute of Medical Research, Australia
- **ROBERT M. STRIETER**
University of Virginia School of Medicine, USA
- **CSABA SZABO**
University of Texas Medical Branch, USA
- **HIROSHI TAKAYANAGI**
University of Tokyo, Japan
- **LEON F. TSENG**
Medical College of Wisconsin, USA
- **ARTHUR VEIS**
Northwestern University, USA
- **FENG-SHENG WANG**
Kaohsiung Chang Gung Memorial Hospital, Taiwan, R.O.C.
- **PING WANG**
The Feinstein Institute for Medical Research, USA
- **GERALD N. WOGAN**
Massachusetts Institute of Technology, USA
- **CHARLES E. WOOD**
University of Florida College of Medicine, USA
- **YOSHIJI YAMADA**
Mie University, Japan
- **MASAYOSHI YAMAGUCHI**
University of Hawaii at Manoa, USA
- **DAZHONG YIN**
Hunan Normal University, P.R. China
- **ROLF MARTIN ZINKERNAGEL**
University of Zurich, Switzerland

177

Upregulation of miR-34a-3p and miR-744-3p is associated with downregulation of PTEN in lymphoblastoid cells from Shwachman-Diamond Syndrome patients

Jessica Gasparello¹, Chiara Papi¹, Giulia Breveglieri¹, Chiara Tupini¹, Elisabetta D'Aversa¹, Valentino Bezzeri², Marco Cipolli², Roberto Gambari¹, Monica Borgatti¹, Alessia Finotti¹

¹Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; ²Cystic Fibrosis Center, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy
E-mail: alessia.finotti@unife.it

Shwachman-Diamond syndrome (SDS) is an inherited disease caused by mutations of a gene encoding for SBDS protein. SDS patients present several hematological disorders, including neutropenia and myelodysplastic syndrome (MDS), with increased risk of leukemic evolution. In lymphoblastoid cells of SDS patients, the already reported upregulated mTOR phosphorylation⁽¹⁾ is possibly associated with the downregulation of PTEN, a validated inhibitor of mTOR phosphorylation. Since PTEN expression might be under the post-transcriptional control of microRNAs⁽²⁾, this study was undertaken to verify the miRNome in SDS patients and find a possible correlation with PTEN gene expression. Lymphoblastoid cell cultures derived from 7 SDS patients and 4 control subjects were studied by Next Generation Sequencing (NGS) and western blot analysis. In total, 11 miRNAs were upregulated in SDS cell cultures compared with controls, according to a 1.5-fold threshold. The differential miRNA expression was further validated by droplet-digital RT-PCR. When the 11 upregulated miRNAs were compared with the 81 validated PTEN-regulating miRNAs (identified using the miRTarBase software: www.mirtarbase.mbc.nctu.edu.tw), two microRNAs were identified: miR-34a-3p and miR-744-3p. In order to relate the PTEN expression with miR-34a-3p and miR-744-3p levels, PTEN was analyzed by RT-qPCR and western blot analysis. The results obtained supported the following conclusions: (a) upregulation of miR-744-3p and miR-34a-3p is variable among SDS cells; (b) PTEN downregulation was found in SDS cells to varying degrees; (c) a correlation does exist between the miR-34a-3p and miR-744-3p levels and PTEN gene expression. Consequently, miR-34a-3p and miR-744-3p are possible targets for increasing PTEN expression in SDS patients.

Acknowledgements: This study was supported by a FIR and a FAR fund of Ferrara University to AF, and by a fund from the Italian Ministry of Health (MOH) to VB, MB and GB.

- (1) Bezzeri V, et al., *Sci Rep* 6: 33165, 2016.
(2) Li W, et al., *J Exp Clin Cancer Res* 37: 223, 2018.

178

Analysis of the miRNome as a possible tool for the detection of autologous blood transfusion misuse in sport

Jessica Gasparello¹, Nicola Lambertini², Chiara Papi¹, Enrica Fabbri¹, Lucia Carmela Cosenza¹, Ilaria Lampronti¹, Fabio Manfredini², Roberto Gambari¹, Alessia Finotti¹

¹Department of Life Sciences and Biotechnology, Ferrara University, Ferrara, Italy; ²Department of Biomedical and Surgical Specialties Sciences - Section of Sport Sciences, Ferrara University, Ferrara, Italy; ³Blood Transfusion Service Azienda Ospedaliera Universitaria Ferrara, Ferrara, Italy
E-mail: alessia.finotti@unife.it

Detection of Autologous Blood Transfusions (ABT) is a key issue in the field of anti-doping for the performance enhancing effects of this prohibited method and the consequent unfair use in sport. Unfortunately, at present no direct detection method of ABT is available. The present study was performed to determine whether the microarray-based analysis of the global miRNA pattern might be useful for the detection of ABT. Blood (500 ml) was drawn from 6 healthy subjects (T2) and then infused after 35 days (T5). Blood samples for microarray analysis of miRNAs were taken 5 days before (T1) and 10 days after blood withdrawal (T3), at day of infusion (T5), and at 3 days (T6) and 15 days (T8) after infusion. For three subjects the withdrawn blood was stored at -80°C, while for the remaining three at +4°C prior to infusion. Global microRNA profiling was performed for a total of 39 RNA samples (extracted from plasma), using the Agilent Human microRNA microarray v.21.0 (no. G4872A). This chip represents 2549 microRNAs, sourced from the miRBase database (Release 21). Microarray results were analyzed using the GeneSpring GX 13 software (Agilent Technologies). Differentially expressed miRNAs were selected following determination of the fold-change analysis, taking T1 as a reference sample. Both up- and downregulated miRNAs were considered. Microarray cluster analysis of informative miRNAs found in plasmas from ABT-trained athletes at T6 and T8 demonstrated that all the ABT T6 and T8 samples are clustered together and differ from T1 and from control samples. These results support the concept that the miRNome analysis might be considered a one-step approach for the detection of ABT.

Acknowledgements: This work was supported by the World Anti Doping Agency Science grant # ISF17D05FM.

179

The possible low cancer risk in schizophrenic patients, through the regulatory role of microRNAs: Preliminary data

E. Rizos¹, N. Siafakas^{2,1}, E. Skourti¹, C. Papageorgiou¹, J. Tsoporis³, Th. Parker⁴, D.A. Spandidos⁵, E. Katsantoni⁶, K. Tsamakis⁷, N. Nikolakakis^{1,2}, V. Zoumpouris³

¹National and Kapodistrian University of Athens, School of Medicine, ²Department of Psychiatry, University General Hospital "ATTIKON", Athens; ³National and Kapodistrian University of Athens, Microbiology Laboratory, University General Hospital "ATTIKON", Athens; ⁴Unit of Biomedical Applications, Institute of Biology, Medical Chemistry and Biotechnology, National Hellenic Research Foundation, ⁵National and Kapodistrian University of Athens, School of Medicine, ⁶Department of Psychiatry, Eginition Hospital, Athens, Greece; ⁷Keenan Research Centre, Li Ka Shing Knowledge Centre, Institute of Biomedical Science, St. Michael's Hospital, Toronto, Canada; ⁸Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion; ⁹Biomedical Research Foundation, Academy of Athens, Hematology-Oncology Division, Athens; ¹⁰Department of Psychiatry and Behavioral Sciences, Faculty of Medicine, University of Crete, Heraklion, Greece
E-mail: erizos@med.uoa.gr

Interest has increased into the role of microRNAs (miRNAs) as regulatory factors in the aetiology and pathophysiology of major psychiatric disorders, such as schizophrenic spectrum disorder, bipolar disorder, depression etc. Reports have indicated a low cancer risk in patients with schizophrenic spectrum disorder and this risk seems to be related to the duration and age of onset of schizophrenia; specifically, duration seems to be inversely correlated with cancer risk. Moreover, other clinical reports have indicated the apoptotic activity of antipsychotics and mainly the First Generation Antipsychotics (FGAs) and thus, an impact on specific gene expression associated with the development of cancer. miRNAs are a large group of small non-coding oligonucleotides that regulate gene expression mainly in the Central Nervous System (CNS). While the development of cancer is characterized by increased gene expression that leads to uncontrolled cell proliferation, the development of schizophrenia is characterized by the opposite phenomenon and specifically, by the reduced expression of genes whose products suppress cellular proliferation and increase apoptosis. Therefore, the regulatory role of miRNA expression is crucial in the development of both of disorders and moreover, miRNAs emerge as a significant etiopathogenic factors and possible biological markers for both disorders and may intermediate this possible negative correlation. This hypothesis is based on their pleiotropic and epistatic function; different subtypes can affect the expression of one gene and one type can act on many targets. In our previous study, we found an implication of let-7, mir-98 and mir-183 as possible biomarkers for cancer and schizophrenia (1,2). The scope of this review was to examine role of miRNAs in the rare co-morbidity of SZ and Ca and to highlight the possible molecular pathways which may be involved on both of these disorders (3). Moreover, new future medicinal strategies could be tested based on miRNA analysis, for both of the disorders, cancer and schizophrenic spectrum disorder.

- (1) Rizos et al., *Oncol Rep* 28: 2200-2204, 2012; (2) Rizos et al., *PLoS One* 10(4): 1-11, 2015; (3) Rizos et al., *Mol Med Rep* 14: 4942-4946, 2016.

180

Monoclonal antibodies to human norovirus that was growing in cell culture

Vladimir Sologub, Irina Koromysova

Research Center for Molecular Diagnostics and Therapy, Department of Biotechnology, Moscow, Russia

Monoclonal antibodies are the main tools for detection of antigens in a large variety of applications in the clinic and literature. Norovirus is a member of the Calicivirus family where many animal models with different biological but with the same morphological or physical properties were described. Replication in cell culture was shown for feline calicivirus and mouse norovirus, but attempts to cultivate human norovirus in cell culture were mainly unsuccessful. We have made successful attempt to cultivate Human Norovirus in monolayer cell culture. The cell culture was the high level of *in vitro* passage fibroblast-like human melanoma. The main property of the cells was their stability at 10 µg/ml of trypsin in serum-free media. Norovirus from fecal samples cause CPE in the cell monolayer after 3-4 days of cultivation at 37°C. Production of the virus was achieved by sandwich ELISA with pair of Mab's produced to Feline and Rabbit Caliciviruses and did not discriminate rabbit and feline viruses. Virus, at the level of 12th passage, was concentrated by ultracentrifugation and purified by CsCl₂ density gradient ultracentrifugation. Then, 100 µg of purified virus in 0.5 ml of PBS was mixed with Complete Freund's Adjuvant and injected into food patties of Balb/c mice. After 1 week, injection of purified virus was repeated and after 3 days popliteal lymph nodes were removed and the lymphocytes were fused with Sp/2-0 mouse myeloma. Hybridomas were detected by indirect ELISA with purified virus and goat anti-mouse IgG-HRP conjugate. In total, 29 clones were chosen and frozen in liquid nitrogen, and 12 Mab's were produced as ascetic fluids. The Mab's were purified by protein A chromatography and sandwich ELISA was used as well as HRP-conjugates of Mab's to generate common Calicivirus epitopes. Very sensitive detection of human norovirus and animal caliciviruses were then obtained by the panel.